TSTickerStarGet alerts

DARE 10-Q filed 2026-11-16 | Key takeaways

DARE filed its 10-Q; the most relevant disclosure change is expanded Nasdaq listing compliance: Company faces delisting risk after receiving delisting determination letter July 13, 2026 for stockholders' equity below $2.5M; received letter October 26, 2026 finding compliance based on August 2026 financing but with heightened quarterly equity requirements.

Share this story

Key takeaways

  • Nasdaq compliance: Company faces delisting risk after Q3 stockholders' equity of ~$2.3M fell below the $2.5M threshold imposed by a Nasdaq Hearings Panel, and stock price closed below $1.00 minimum bid price requirement on September 30, 2026.

  • Finance lease extended: Clean Room Agreement lease term extended from December 2026 to December 2027, increasing finance lease ROU asset and liability by approximately $1.9M.

  • August 2026 financing: Raised $5.4M net from offering of 4.1M common shares and warrants; stockholder approval received November 10, 2026 allowing warrant exercise.

  • Ovaprene Phase 3 protocol amended: FDA approved removal of 250 completer expectation; study continues with DSMB recommending continuation based on interim safety data showing approximately 9% pregnancy rate.

  • DARE to PLAY launch: Dispensing expected to begin November 2026 in 28 states; company expects non-material revenue during 2026.

  • Consumer health revenue: Began recording revenue from Flora Sync LF5 sales in July 2026, with nominal Q3 revenue.

  • Grant funding received: ~$0.9M received November 13, 2026 under 2024 contraceptive grant (cumulative ~$9.9M of ~$10.7M); ~$1.5M received October 2026 under 2021 DARE-LARC1 grant (cumulative ~$43.3M of ~$49M).

Key metrics

Net loss - Q3Q3 2026
$3.16Mimproved from $3.56M
Net loss - YTDNine months 2026
$9.14Mimproved from $11.96M
Loss per common share - basic and diluted - Q3Q3 2026
-$0.18improved from -$0.28
Loss per common share - basic and diluted - YTDNine months 2026
-$0.59improved from -$1.18
Research and development services and other revenue - Q3Q3 2026
$47,628increased from $2,262
Research and development services and other revenue - YTDNine months 2026
$387,629increased from $6,517
Net cash used in operating activities - YTDNine months 2026
-$19.14Mincreased from -$11.47M
Cash and cash equivalentsSeptember 30, 2026
$11.53Mdecreased from $24.71M at Dec 31, 2025

Disclosure changes

  • Nasdaq listing compliance

    Company faces delisting risk after receiving delisting determination letter July 13, 2026 for stockholders' equity below $2.5M; received letter October 26, 2026 finding compliance based on August 2026 financing but with heightened quarterly equity requirements through end of 2027; as of September 30, 2026, stockholders' equity was below required projected level, expecting new delisting determination letter; separate September 28, 2026 letter notified company of bid price below $1.00 for 30 consecutive business d...

    Nasdaq listing status directly impacts stock liquidity, ability to raise capital, and stockholder value; potential delisting could substantially impair ability to raise additional capital.
  • Finance lease modification

    Clean Room Agreement lease extended from December 31, 2026 to December 31, 2027; accounted for as lease modification with remeasurement using incremental borrowing rate at modification date, resulting in approximately $1.9M increase to both finance lease ROU asset and finance lease liability.

    Extension provides continued controlled clean room space for product development; $1.9M increase in lease liability affects future cash obligations.
  • August 2026 financing completion

    Closed August 17, 2026 on securities purchase agreement for 4,085,687 common shares at $1.37/share and pre-funded warrants for 293,894 shares at $1.3699/share; investors received Series A Warrants (4,379,581 shares at $1.37) and Series B Warrants (4,379,581 shares at $1.37); pre-funded warrants exercised immediately at $0.0001/share; gross proceeds ~$6.0M, net proceeds ~$5.4M; stockholder approval for warrant exercise received November 10, 2026.

    Primary capital raise in Q3 2026; significant dilution from warrant issuances (now 10.88M warrants outstanding vs 1.27M at Dec 31, 2025); stockholder approval enabled warrant exercisability.
  • Series A Convertible Preferred Stock

    Certificate of designation filed January 23, 2026 designating 4,999,620 shares as Series A Preferred Stock; each share has $5.00 stated value and liquidation preference, convertible at holder's option into common stock at $2.50/share; no voting rights; no dividends unless declared; 78,000 shares outstanding at September 30, 2026.

    New financing instrument providing capital; potential conversion creates future dilution; 78,000 shares outstanding convertible to 156,000 common shares.
  • Regulation A Offering

    Regulation A Offering initiated January 2026 offering up to 4,854,000 units at $5.00/unit; each unit consists of one share Series A Preferred Stock and two warrants to purchase common stock at $4.00/share; through September 30, 2026, issued 338,000 units for gross proceeds ~$1.7M, net proceeds ~$1.5M; Investor Warrants exercisable 36 months from issuance at $4.00/share.

    Ongoing capital raise vehicle; 338,000 shares of preferred stock and 676,000 warrants issued YTD; additional potential dilution.
  • Ovaprene Phase 3 protocol amendment

    FDA approved protocol amendment in August 2026 to remove specific expectation of at least 250 completers from Phase 3 study; study protocol amended Q3 2026; DSMB conducted second planned interim analysis May 2026 recommending study continue without modification; interim data showed approximately 9% pregnancy rate, no new adverse event types, approximately 12% discontinued due to vaginal odor (down from 17%); study expected to achieve 2,500 cycles of exposure in 2027 supporting topline data announcement.

    Key clinical milestone; FDA approval of protocol amendment removes potential enrollment barrier; topline data expected 2027 represents significant upcoming catalyst.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow DARE in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert